:Potassium    (DrugBank: Potassium)

10 diseases
告示番号疾患名(ページ内リンク)臨床試験数
36表皮水疱症2
46悪性関節リウマチ1
66IgA腎症1
67多発性嚢胞腎1
98好酸球性消化管疾患2
115遺伝性周期性四肢麻痺1
167マルファン症候群4
179ウィリアムズ症候群1
215ファロー四徴症1
235副甲状腺機能低下症1

36. 表皮水疱症 [臨床試験数:147,薬物数:170(DrugBank:40),標的遺伝子数:32,標的パスウェイ数:113
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 147 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-003670-32-AT05/10/201707/08/2017Phase I/II trial to establish safety, tolerability and efficacy of losartan in children with epidermolysis bullosaA dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB) - REFLECT Recessive dystrophic epidermolysis bullosa (RDEB)
MedDRA version: 20.0Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Losartan HEXAL
INN or Proposed INN: losartan potassium
Other descriptive name: LOSARTAN POTASSIUM
Medical Center - University of FreiburgNULLNot RecruitingFemale: yes
Male: yes
30Phase 2Austria;Germany
2EUCTR2015-003670-32-DE07/04/2016Phase I/II trial to establish safety, tolerability and efficacy of losartan in children with epidermolysis bullosaA dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB) - REFLECT Recessive dystrophic epidermolysis bullosa (RDEB)
MedDRA version: 20.0Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Losartan HEXAL
INN or Proposed INN: losartan potassium
Other descriptive name: LOSARTAN POTASSIUM
Medical Center - University of FreiburgNULLNAFemale: yes
Male: yes
30Phase 2Austria;Germany

46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4,183 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00461448February 200717/4/2007A Pilot Study of Potassium Supplementation for Adult Patients With Rheumatoid ArthritisPilot Study of Potassium Supplementation in the Treatment of Rheumatoid Arthritis: a 4-Week, Randomized, Double-Blind, Placebo-Controlled TrialRheumatoid ArthritisDietary Supplement: Potassium supplementShahid Beheshti Medical UniversityNULLCompleted18 Years60 YearsBoth36Phase 1Iran, Islamic Republic of

66. IgA腎症 [臨床試験数:199,薬物数:214(DrugBank:57),標的遺伝子数:32,標的パスウェイ数:128
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 199 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-IIR-170134872018-01-012017-11-22A multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantabA multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantab IgA nephropathyExperimental group:Zhengqing Fengtongning extantab;Control group 1:Losartan Potassium Tablets;Control group 2:Losartan Potassium Tablets + Zhengqing Fengtongning extantab;The Third Xiangya Hospital of Central South UniversityNULLRecruiting1870BothExperimental group:36;Control group 1:36;Control group 2:36;4 (Phase 4 study)China

67. 多発性嚢胞腎 [臨床試験数:186,薬物数:196(DrugBank:47),標的遺伝子数:35,標的パスウェイ数:146
Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 186 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TRC-110012822011-04-012011-04-21Triptolide Retards Autosomal Dominant Polycystic Kidney Disease with ProteinuriaTriptolide Retards Autosomal Dominant Polycystic Kidney Disease with Proteinuria Autosomal dominant polycystic kidney disease;Q61.301Group A:Glucosidorum Tripterygll Totorum+losartan potassium ;Group B:Placebo + losartan potassium;Shanghai Changzheng HospitalNULLCompleted1855BothGroup A:30;Group B:30;China

98. 好酸球性消化管疾患 [臨床試験数:128,薬物数:147(DrugBank:40),標的遺伝子数:34,標的パスウェイ数:132
Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "N-FPIES"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 128 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03029091May 23, 201720/1/2017An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue DisorderEosinophilic EsophagitisDrug: Losartan PotassiumChildren's Hospital Medical Center, CincinnatiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institute of Allergy and Infectious Diseases (NIAID);Office of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS)Completed5 Years25 YearsAll15Phase 2United States
2NCT01808196October 10, 201330/1/2013Testing Effectiveness of Losartan in Patients With EoE With or Without a CTDA Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.Eosinophilic Esophagitis;Connective Tissue DisordersDrug: Losartan PotassiumChildren's Hospital Medical Center, CincinnatiNULLCompleted5 Years21 YearsAll6Phase 2United States

115. 遺伝性周期性四肢麻痺 [臨床試験数:1,薬物数:2(DrugBank:2),標的遺伝子数:13,標的パスウェイ数:7
Searched query = "Hereditary periodic paralysis", "Hereditary Hypokalemic Periodic Paralysis", "Andersen-Tawil syndrome", "Hereditary Hyperkalemic Periodic Paralysis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00839501December 20085/2/2009Effect of Potassium and Acetazolamide on People With Andersen-Tawil SyndromeTherapeutic Trial of Potassium and Acetazolamide in Andersen-Tawil SyndromeAndersen-Tawil SyndromeDietary Supplement: Potassium;Drug: AcetazolamideUniversity of RochesterOffice of Rare Diseases (ORD);Rare Diseases Clinical Research Network;National Institute of Neurological Disorders and Stroke (NINDS)Terminated10 YearsN/ABoth3Phase 1United States;United Kingdom

167. マルファン症候群 [臨床試験数:19,薬物数:38(DrugBank:10),標的遺伝子数:10,標的パスウェイ数:49
Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 19 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-005862-10-BE29/05/200907/01/2009Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers.Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. Marfan syndrome
MedDRA version: 9.1Level: LLTClassification code 10026829Term: Marfan's syndrome
Trade Name: Cozaar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
Trade Name: Coozar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
Trade Name: Coozar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
University Hospital GhentNULLNot RecruitingFemale: yes
Male: yes
Belgium
2EUCTR2007-001125-97-ES20/05/200803/12/2007Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome)Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol
MedDRA version: 9.1Level: LLTClassification code 10026829Term: Marfan's syndrome
Trade Name: cozaar 50
INN or Proposed INN: LOSARTAN POTASSIUM
Trade Name: blokium 50
INN or Proposed INN: ATENOLOL
Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula
INN or Proposed INN: LOSARTAN POTASSIUM
Trade Name: BLOKIUM 50 mg comprimidos
INN or Proposed INN: ATENOLOL
alberto fortezaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Spain
3NCT00429364January 200729/1/2007Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart NetworkTrial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)Marfan SyndromeDrug: Losartan Potassium;Drug: AtenololNew England Research InstitutesNational Heart, Lung, and Blood Institute (NHLBI);FDA Office of Orphan Products Development;National Marfan FoundationCompleted6 Months25 YearsAll608Phase 3United States;Belgium;Canada
4EUCTR2006-003991-37-BE13/12/200606/12/2006Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan TrialTrial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial Marfan syndrome
MedDRA version: 8.1Level: LLTClassification code 10026829Term: Marfan's syndrome
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: Atenolol
INN or Proposed INN: Atenolol
Product Name: Atenolol
INN or Proposed INN: Atenolol
Product Name: Atenolol
INN or Proposed INN: Atenolol
University Hospital GentNULLNot RecruitingFemale: yes
Male: yes
600Belgium

179. ウィリアムズ症候群 [臨床試験数:4,薬物数:13(DrugBank:7),標的遺伝子数:8,標的パスウェイ数:32
Searched query = "Williams syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-006059-37-ES27/05/200919/08/2008ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMSENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS Pacientes con síndrome de Williams con evidencia molecular de microdeleción en 7q11.2. Edad: Niños de más de 5 años y adultos Sexo: ambos sexos estarán representados lo más paritariemente posible Variante molecular de la deleción que confirme la presencia de 2 o más copias del gen NCF1.
MedDRA version: 9.1Level: LLTClassification code 10049644Term: Williams syndrome
Trade Name: COZAAR 50 mg comprimidos recubierto con pelicula
INN or Proposed INN: LOSARTAN POTASICO
Other descriptive name: LOSARTAN POTASSIUM
Programa de Medicina Molecular y Genética, Hospital Vall d´HebronNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Spain

215. ファロー四徴症 [臨床試験数:19,薬物数:35(DrugBank:16),標的遺伝子数:16,標的パスウェイ数:47
Searched query = "Tetralogy of Fallot", "Fallot tetralogy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 19 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-002091-41-NL09/10/201405/11/2013Research into the effect of the drug losartan in adult patients with a reduced function of the right cardiac chamber and a cardiac birth defectRight vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system - Redefine trial To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions.;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Trade Name: Losartan
Product Name: Losartan
INN or Proposed INN: Losartan Potassium
Other descriptive name: LOSARTAN POTASSIUM
Academisch medisch centrumNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands

235. 副甲状腺機能低下症 [臨床試験数:67,薬物数:112(DrugBank:24),標的遺伝子数:4,標的パスウェイ数:5
Searched query = "Hypoparathyroidism", "Accessory thyroid hypergasia disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 67 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02824718June 6, 20171/7/2016Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary HypoparathyroidismA Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary HypoparathyroidismAutosomal Dominant Hypocalcemia or OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under TreatmentDrug: Teriparatide;Drug: Thiazide;Drug: Potassium sparing diuretic;Drug: AlfacalcidolAssistance Publique - Hôpitaux de ParisMinistry of Health, FranceRecruiting18 Years80 YearsAll12Phase 2France